Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

NCT07389941 on ClinicalTrials.gov · last registry update 2026-02-11

An unusually large phase 4: 240 participants, more than double the 75 typical for the stage. Due to report April 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Luebeck
Sponsor type: Other
Enrollment: 240
Started: 2026-10
Primary completion: 2029-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)

Conditions studied

Atrial Fibrillation (AF)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.